As a leader in oncology in the UK and Ireland, Bristol Myers Squibb is committed to advancing cancer care. Across a broad range of solid tumours and blood cancers, we strive to help more patients with our medicines, scientific discovery and investigational research.
We have a broad and bold approach to cancer and our scientists are exploring different approaches to develop the next generation of therapeutic options in metastatic and early-stage cancers.
Enhancing diversity and inclusion to tackle cancer inequalities
Cancer inequalities are estimated to lead to around 30,000 more cancer cases in the UK each year.1 At Bristol Myers Squibb, we promote health equity and seek to improve the health outcomes of populations disproportionately affected by serious diseases. We are committed to reflecting diverse patient populations in our clinical trials and supporting activities to address long-standing cancer inequalities. We are also committing to identifying areas of opportunity to provide practical solutions to help people living with cancer access the services, information and support that they need today and in the future.
